CAMP4 Therapeutics (CAMP) News
NASDAQ: CAMPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CAMP news summary
We found 4 recent headlines mentioning CAMP4 Therapeutics (CAMP): 1 in the past week and 3 in the past 30 days, most often from GlobeNewswire, Nasdaq. CAMP is making an outsized move today, down 5.25% at $3.79, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", was published by GlobeNewswire on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest CAMP4 Therapeutics headlines
- CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)WATERTOWN, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of…GlobeNewswire
- CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European UnionApproval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002GlobeNewswire
- Raymond James Initiates Coverage of Camp4 Therapeutics with Strong BuyFintel reports that on October 23, 2026, Raymond James initiated coverage of Camp4 Therapeutics (NASDAQGM:CAMP) with a Strong Buy recommendation. CalAmp Corp., based in the United States, operates…Nasdaq
- CAMP4 to Participate in Chardan’s 10th Annual Healthcare ConferenceWATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory…GlobeNewswire